

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	mation		
1. Given Name (First Name) Harry	2. Surname (Last Name) Buller		3. Date 24-October-2017
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Na Gary Raskob	ame
5. Manuscript Title Edoxaban for the Treatment of Cance	r-Associated Venous Thror	nboembolism	
6. Manuscript Identifying Number (if you l 17-11948	know it)		
		_	
Section 2. The Work Under 0	Consideration for Publi	cation	
Did you or your institution at any time recany aspect of the submitted work (includir statistical analysis, etc.)?	ng but not limited to grants, d		
Are there any relevant conflicts of inte		.1	
If yes, please fill out the appropriate in Excess rows can be removed by pressi	•	ve more than one entity pro	ess the "ADD" button to add a row.
Name of Institution/Company	Grant'	n-Financial Other? Co	mments
Daiichi-Sankyo		Cons	ultant fees, honoraria
Section 3. Relevant financia	l activities outside the	submitted work.	
Place a check in the appropriate boxes of compensation) with entities as described the "Add +" box. You should re	ribed in the instructions. U eport relationships that we	se one line for each entity;	add as many lines as you need by
Are there any relevant conflicts of inte If yes, please fill out the appropriate in			
ii yes, picase iiii out the appropriate iii	Totalidation below.		
Name of Entity	Grant	n-Financial Other? Co	mments
Bayer Healthcare		Cons	sultant, honoraria
BMS/Pfizer		Cons	sultant, honoraria
Boehringer-Ingelheim		Cons	ultant, honoraria



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Portola		✓			Consultant	
Medscape		✓			Honoraria	
Eli Lilly		\checkmark			Consultant	
Sanofi Aventis		\checkmark			Consultant	
lonis		\checkmark			Consultant	
Section 4. Intellectual Proper	ty Pate	ents & Cop	pyrights			
Do you have any patents, whether planr	ned, pend	ing or issue	ed, broadly releva	nt to the	work? Yes 🗸 No	
Section 5. Relationships not	covered	above				
Are there other relationships or activities potentially influencing, what you wrote				nfluence	d, or that give the appearance of	
Yes, the following relationships/cond	ditions/cir	cumstance	es are present (exp	olain belo	ow):	
No other relationships/conditions/ci	rcumstan	ces that pre	esent a potential	conflict o	finterest	
At the time of manuscript acceptance, jo On occasion, journals may ask authors to						ents.
Section 6. Disclosure Stateme	ent					
Based on the above disclosures, this form below.	n will auto	omatically (generate a disclos	sure state	ment, which will appear in the box	
Dr. Buller reports personal fees from Da personal fees from BMS/Pfizer, personal Medscape, personal fees from Eli Lilly, p work.	fees from	n Boehringe	er-Ingelheim, pers	sonal fees	from Portola, personal fees from	



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	mation		
1. Given Name (First Name) Mark	2. Surname (Last Name) Carrier		3. Date 24-October-2017
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Auth	nor's Name
5. Manuscript Title Edoxaban for the Treatment of Cance	r-Associated Venous Thron	nboembolism	
6. Manuscript Identifying Number (if you l 17-11948	know it)		
Section 2. The Work Under (Consideration for Publi	cation	
Did you or your institution at any time recany aspect of the submitted work (includir statistical analysis, etc.)?			nent, commercial, private foundation, etc.) for tudy design, manuscript preparation,
Are there any relevant conflicts of inte			
If yes, please fill out the appropriate in Excess rows can be removed by pressi	•	e more than one en	tity press the "ADD" button to add a row.
Name of Institution/Company	Grant'	n-Financial Support	Comments
Daiichi Sankyo			Consultant fees
Section 3. Relevant financia	l activities outside the	submitted work.	
	ribed in the instructions. Useport relationships that we rest?	se one line for each e	icial relationships (regardless of amount entity; add as many lines as you need by ne 36 months prior to publication.
Name of Entity	Grant•	n-Financial Support?	Comments
BMS	✓		Research grant and consultant fees
EO Pharma	✓		Research grant and consultant fees
Pfizer			Consultant, honoraria



Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other? Comments	
Sanofi			Consultant, honoraria	
Bayer			Consultant, honoraria	
Continu A				
Section 4. Intellectual Propert	y Patents & Co	pyrights		
Do you have any patents, whether plann	ed, pending or issue	ed, broadly releva	nt to the work? ☐ Yes ✓	No
Section 5. Relationships not c	overed above			
Are there other relationships or activities potentially influencing, what you wrote in Yes, the following relationships/conditions/cir No other relationships/conditions/cir At the time of manuscript acceptance, journals may ask authors to	n the submitted wo litions/circumstance cumstances that pro urnals will ask autho	rk? es are present (expessent a potential of ors to confirm and	olain below): conflict of interest d, if necessary, update their disc	
Section 6. Disclosure Statemen	nt			
Based on the above disclosures, this form below.	າ will automatically (generate a disclos	sure statement, which will app	ear in the box
Dr. Carrier reports personal fees from Da grants and personal fees from LEO Pharr Bayer outside the submitted work.				



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency **Licensed:** The patent has been licensed to an entity, whether

earning royalties or not **Royalties:** Funds are coming in to you or your institution due to your

patent

Di Nisio 1



Section 1.	Identifying Inform	nation					
1. Given Name (Fi Marcello	rst Name)	2. Surname (Last Name Di Nisio	e) 3. Date 25-October-2017				
4. Are you the cor	responding author?	☐ Yes ✓ No	Corresponding Author's Name Gary Raskob				
5. Manuscript Title Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism							
6. Manuscript Ider 17-11948	ntifying Number (if you kr	now it)					
	l						
Section 2.	The Work Under Co	onsideration for Pu	blication				
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No							
Section 3. Relevant financial activities outside the submitted work.							
of compensation clicking the "Add Are there any rel) with entities as descri	ibed in the instructions port relationships that est?	whether you have financial relationships (regardless of amount s. Use one line for each entity; add as many lines as you need by were present during the 36 months prior to publication .				
Name of Entity		Grant? Personal Fees?	Non-Financial Other? Comments				
Daiichi Sankyo			Consultant, honoraria				
Section 4.	Intellectual Proper	rty Patents & Cop	yrights				
Do you have any	patents, whether plan	ned, pending or issued	d, broadly relevant to the work? Yes V No				

Di Nisio 2



Section 5. Polationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Di Nisio reports personal fees from Daiichi Sankyo outside the submitted work.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Di Nisio 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	ation			
1. Given Name (First Name) David	2. Surname (Last Nan Garcia	ne)	3. Date 24-October-2017	
4. Are you the corresponding author?	Yes ✓ No	Correspond Gary Rasko	ling Author's Name ob	
5. Manuscript Title Edoxaban for the Treatment of Cancer-	Associated Venous TI	nromboembolism	1	
6. Manuscript Identifying Number (if you kno	ow it)			
Section 2. The Work Under Co				
The Work Under Co	nsideration for P	ublication		
	but not limited to gran		government, commercial, private foundation, etc.) board, study design, manuscript preparation,	for
If yes, please fill out the appropriate info Excess rows can be removed by pressing	-	ı have more than	one entity press the "ADD" button to add a ro	ow.
Name of Institution/Company	Grant? Personal Fees?	Non-Financial Support?	Other? Comments	
Daiichi Sankyo	✓		Consultant fees, honoraria; research payments to my institution	
Section 3. Relevant financial a	activities outside t	he submitted v		
of compensation) with entities as describ clicking the "Add +" box. You should rep	oed in the instructior ort relationships tha	ns. Use one line fo t were present d u	ve financial relationships (regardless of amou or each entity; add as many lines as you need b oring the 36 months prior to publication.	
Are there any relevant conflicts of intere If yes, please fill out the appropriate info		No		
ii yes, piease iiii out the appropriate iiiio	illiation below.			
Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other? Comments	
BMS			Consultant	
Boehringer-Ingelheim			Consultant	
Janssen	✓		Consultant; research fees paid to my institution	



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments		
Pfizer		✓			Consultant, honoraria		
Medscape		\checkmark			Honoraria		
Incyte	√	√			Research fees paid to my institution; consultant, honoraria		
Section 4. Intellectual Propert	y Pate	ents & Cop	pyrights				
Do you have any patents, whether plann	ed, pend	ing or issue	ed, broadly releva	nt to the	work?		
	•		,				
Section 5. Relationships not o	overed	above					
Are there other relationships or activities potentially influencing, what you wrote i				nfluence	d, or that give the appearance of		
Yes, the following relationships/cond	litions/cir	cumstance	es are present (exp	olain belo	ow):		
✓ No other relationships/conditions/cir	cumstan	ces that pre	esent a potential (conflict o	finterest		
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.							
Section 6. Disclosure Statemen	4						
Disclosure Stateme							
Based on the above disclosures, this forn below.	n will auto	omatically (generate a disclos	sure state	ement, which will appear in the box		
Dr. Garcia reports grants and personal fe personal fees from Boehringer-Ingelheir from Medscape, and grants and persona	n, grants	and persor	nal fees from Jans	sen, pers	onal fees from Pfizer, personal fees		



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Grosso 1



Section 1.	Identifying Inform	nation				
1. Given Name (Fi Michael	rst Name)	2. Surname (Last Name) Grosso		3. Date 24-October-2017		
4. Are you the cor	responding author?	☐ Yes ✓ No	Corresponding Author	's Name		
5. Manuscript Title Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism						
6. Manuscript Ider 17-11948	ntifying Number (if you kr	now it)				
	ı					
Section 2.	The Work Under Co	onsideration for Publi	cation			
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No						
Section 3.	Relevant financial	activities outside the	submitted work.			
of compensation clicking the "Add Are there any rel) with entities as descri	bed in the instructions. Upper that we lest? Yes No	se one line for each ent	al relationships (regardless of amount ity; add as many lines as you need by 36 months prior to publication .		
Name of Entity		Grant	n-Financial upport?	Comments		
Daiichi Sankyo				Daiichi Sankyo employee		
Section 4.	Intellectual Proper	rty Patents & Copyri	ghts			
Do you have any	patents, whether plan	ned, pending or issued, bı	oadly relevant to the w	vork? ☐ Yes 🗸 No		

Grosso 2



Section 5. Polationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Grosso reports personal fees from Daiichi Sankyo outside the submitted work.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Grosso 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Info	ormation	
1. Given Name (First Name) Ajay	2. Surname (Last Name) Kakkar	3. Date 24-October-2017
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name Gary Raskob
5. Manuscript Title Edoxaban for the Treatment of Can	cer-Associated Venous Thron	nboembolism
6. Manuscript Identifying Number (if yo 17-11948	u know it)	_
Section 2. The Week Under		
The Work Unde	r Consideration for Publi	cation
		n a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of in		
If yes, please fill out the appropriate Excess rows can be removed by pres		ve more than one entity press the "ADD" button to add a row.
Name of Institution/Company	Grant	n-Financial Other? Comments
Daiichi Sankyo		Member of steering committee. Honorarium paid through Iteras
Section 3. Relevant finance	ial activities outside the	submitted work.
of compensation) with entities as de	escribed in the instructions. U I report relationships that we terest?	nether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication .
Name of Entity	Grant	n-Financial Other? Comments
Bayer AG	✓	Research grant to Thrombosis Research Institute for Garfield Study. Honoraria and consulting fees
Boehringer-Ingelheim		Consulting fees and Honoraria



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
anssen Pharma		✓			consulting fees and Honoraria	
anofi SA		✓			consulting fees and Honoraria	
/erseon		✓			consulting fees	
Section 4. Intellectual Bronout						
Intellectual Propert	y Pate	ents & Cop	pyrights			
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume No						
Section 5. Relationships not c	overed	above				
Are there other relationships or activities potentially influencing, what you wrote i				nfluence	d, or that give the appearance of	
Yes, the following relationships/cond	itions/cir	cumstance	es are present (exp	olain belc	ow):	
✓ No other relationships/conditions/cir	cumstan	ces that pre	esent a potential o	conflict o	finterest	
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.						
Section 6. Disclosure Stateme	nt					
Based on the above disclosures, this form below.	n will auto	omatically (generate a disclos	sure state	ment, which will appear in the box	
Dr. Kakkar reports personal fees from Da AG, personal fees from Boehringer-Ingel personal fees from Verseon outside the s	heim, pe	rsonal fees				



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Kovacs 1



	I							
Section 1.	Identifying Information							
1. Given Name (First Name) Michael		2. Surname (Last Name) Kovacs						
4. Are you the corresponding author?		☐ Yes ✓ No	Corresponding Author	orresponding Author's Name ary Raskob				
5. Manuscript Title Edoxaban for th		r-Associated Venous Thron	nboembolism					
6. Manuscript ldei 17-11948	ntifying Number (if you k	(now it)						
	ı							
Section 2.	The Work Under (Consideration for Publi	ication					
any aspect of the s statistical analysis,	ubmitted work (includin	g but not limited to grants, d		ent, commercial, private foundation, udy design, manuscript preparation,				
Section 3.	Relevant financia	activities outside the	submitted work.					
of compensation clicking the "Ado Are there any rel	n) with entities as desc	ribed in the instructions. Ueport relationships that we rest?	Ise one line for each e	cial relationships (regardless of an ntity; add as many lines as you ne e 36 months prior to publicatio	ed by			
Name of Entity		Grant? Personal No	on-Financial Support?	Comments				
Pfizer		✓		Honorarium				
Bayer		✓		Honorarium				
Daiichi Sankyo Pharma		✓						
Bristol Meyers Squibb								

Kovacs 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume No
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Kovacs reports grants and personal fees from Pfizer, grants and personal fees from Bayer, grants from Daiichi Sankyo Pharma, and grants from Bristol Meyers Squibb outside the submitted work.

Evaluation and Feedback

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$

Kovacs 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Mercuri 1



Section 1.	Identifying Inform	nation				
Given Name (First Name) Michele		2. Surname (Last Name) Mercuri	3. Date 24-October-2017			
4. Are you the corresponding author?		☐ Yes ✓ No	Corresponding Author's Name Gary Raskob			
5. Manuscript Title Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism						
6. Manuscript Ider 17-11948	ntifying Number (if you kr	now it)				
	l					
Section 2.	The Work Under Co	onsideration for Pub	lication			
any aspect of the s statistical analysis, Are there any rel	ubmitted work (including	but not limited to grants,	om a third party (government, commercial, private foundation, e data monitoring board, study design, manuscript preparation,	tc.) for		
Section 3.	Relevant financial	activities outside the	e submitted work.			
of compensation clicking the "Add Are there any rele) with entities as descri	ibed in the instructions. port relationships that w est?	whether you have financial relationships (regardless of am Use one line for each entity; add as many lines as you nee were present during the 36 months prior to publication	ed by		
Name of Entity		Grant? Personal Fees?	Other? Comments			
Daiichi-Sankyo			Employment and compensation			
Section 4.	Intellectual Proper	rty Patents & Copy	rights			
Do you have any	patents, whether plan	ned, pending or issued,	broadly relevant to the work? Yes V No			

Mercuri 2



Section 5. Relationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Mercuri reports personal fees from Daiichi-Sankyo, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Mercuri 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Meyer 1



Section 1. Identifying Inform	nation					
1. Given Name (First Name) Guy	2. Surname (Last Name) Meyer	3. Date 25-October-2017				
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Author's Name Gary Raskob				
5. Manuscript Title Edoxaban for the Treatment of Cancer-	Associated Venous Thron	nboembolism				
6. Manuscript Identifying Number (if you kr 17-11948	now it)	_				
Section 2. The Work Under Co	onsideration for Publi	cation				
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, da	. , .	•	tc.) for		
Section 3. Relevant financial	activities outside the s	submitted work.				
Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should repart there any relevant conflicts of interesting the propriate info	ibed in the instructions. Use port relationships that we lest? Yes No primation below.	se one line for each enti re present during the 3	ity; add as many lines as you nee	d by		
Name of Entity	Grant? Personal Fees? S	n-Financial other?	Comments			
Leo Pharma		T	ravel support			
BMS-Pfizer	✓	✓ T	ravel Support			
Stago		✓ T	ravel Support			
Bayer Healthcare		✓	ravel Support	7		

Meyer 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Meyer reports non-financial support from Leo Pharma, grants and non-financial support from BMS-Pfizer, non-financial support from Stago, and non-financial support from Bayer Healthcare outside the submitted work.

Evaluation and Feedback

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$

Meyer 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1.	Identifying Information								
Given Name (First Name) Gary		2. Surname (Last N	lame)	3. Date 24-October-2017					
4. Are you the corresponding author?		✓ Yes No)						
5. Manuscript Title Edoxaban for th	e ne Treatment of Cancer	r-Associated Venous	s Thromboembolis	m					
6. Manuscript Ide 17-11948	ntifying Number (if you k	now it)							
Section 2.	The Work Under C	onsideration for	Publication						
	submitted work (including				ent, commercial, private foundation, etc.) for udy design, manuscript preparation,				
-	evant conflicts of inter	rest? ✓ Yes	No						
		· · · · · · · · · · · · · · · · · · ·	ou have more tha	n one enti	ty press the "ADD" button to add a row.				
excess rows can	be removed by pressir								
Name of Institut	tion/Company	Grant? Person Fees		Other?	Comments				
Daiichi Sankyo					Consultant fees, honoraria				
Section 3.	Relevant financial	activities outsid	e the submitted	l work.					
of compensation	n) with entities as descr	ribed in the instruct	ions. Use one line t	for each er	cial relationships (regardless of amount ntity; add as many lines as you need by e 36 months prior to publication.				
Are there any relevant conflicts of interest? Yes No									
If yes, please fill o	out the appropriate inf	ormation below.							
Name of Entity		Grant? Person		Other?	Comments				
Bayer Healthcare					Consultant, honoraria				
BMS					Consultant, honoraria				
Boehringer-Ingelheim					Consultant				



Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments	
Eli Lilly		✓			Consultant	
Janssen		✓			Consultant	
Johnson and Johnson		✓			Consultant	
Pfizer		√			Consultant, honoraria	
Portola		\checkmark			Consultant	
Merck		✓			Consultant	
Medscape		✓			Honoraria	
Section 4. Intellectual Propert	ty Pate	ents & Cop	pyrights			
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume No.						
Relationships not c						
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?						
Yes, the following relationships/cond	ditions/cir	cumstance	es are present (exp	olain belo	w):	
✓ No other relationships/conditions/cit	rcumstan	ces that pre	esent a potential	conflict o	finterest	
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.						
Section 6. Disclosure Stateme	nt					
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.						
Dr. Raskob reports personal fees from Daiichi Sankyo during the conduct of the study; personal fees from Bayer Healthcare, personal fees from BMS, personal fees from Boehringer-Ingelheim, personal fees from Eli Lilly, personal fees from Janssen, personal fees from Johnson and Johnson, personal fees from Portola, personal fees from Merck, and personal fees from Medscape outside the submitted work.						



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Segers 1



Continue					
Section 1. Identifying Inform	mation				
Given Name (First Name) Annelise	2. Surname (Last Name) Segers		3. Date 25-October-2017		
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name Gary Raskob			
5. Manuscript Title Edoxaban for the Treatment of Cance	r-Associated Venous Thror	nboembolism			
6. Manuscript Identifying Number (if you k 17-11948	know it)	_			
Section 2. The Work Under (Consideration for Publi	cation			
any aspect of the submitted work (includin statistical analysis, etc.)? Are there any relevant conflicts of inte If yes, please fill out the appropriate in	ng but not limited to grants, doesn't be seen to	ata monitoring board, st	ent, commercial, private foundation, etc.) fo cudy design, manuscript preparation, ity press the "ADD" button to add a row		
Excess rows can be removed by pressi					
Name of Institution/Company	Grant'	on-Financial Other?	Comments		
aiichi Sankyo	✓		Director of ITREAS (an Academic Research Organization (ARO)). ITREAS received payments of Daiichi Sankyo for the scientific coordination of the study.		
Section 3. Polovont financial activities outside the submitted work					
Section 5. Delevent time and					
Relevant financia	l activities outside the	submitted work.			

Segers 2



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
IONIS Pharmaceuticals	V				Medical Director of ITREAS (an ARO). ITREAS received payments of IONIS for the scientific coordination of the study	
Daiichi Sankyo	✓				Medical Director of ITREAS (an ARO). ITREAS received payments of Daiichi Sankyo for the scientific coordination of other Phase 2 studies	
Janssen Pharmaceuticals	✓				Medical Director of ITREAS (an ARO). ITREAS receives payments of Janssen for the scientific coordination of a Phase 2 study	
Section 4. Intellectual Proper	ty Pate	ents & Co	pyrights			
Do you have any patents, whether planr	ied, pend	ing or issue	ed, broadly releva	nt to the	work? Yes 🗸 No	
Section 5. Relationships not o	overed	above				
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?						
Yes, the following relationships/cond	ditions/cir	cumstance	es are present (exp	olain belo	w):	
No other relationships/conditions/ci	rcumstan	ces that pre	esent a potential o	conflict o	finterest	
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.						
Section 6. Disclosure Stateme	nt					
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.						
Dr. Segers reports grants from Daiichi Sankyo during the conduct of the study; grants from IONIS Pharmaceuticals, grants from Daiichi Sankyo, and grants from Janssen Pharmaceuticals outside the submitted work.						

Segers 3



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Segers 4



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Shi 1



Section 1. Identifying Inform	nation	
Given Name (First Name) Minggao	2. Surname (Last Name) Shi	3. Date 25-October-2017
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Gary Raskob
5. Manuscript Title Edoxaban for the Treatment of Cancer-	-Associated Venous Thron	nboembolism
6. Manuscript Identifying Number (if you kr 17-11948	now it)	_
Section 2. The Work Under Co	onsideration for Publi	cation
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ita monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the	submitted work.
of compensation) with entities as descri	ibed in the instructions. Upport relationships that we lest? Yes No	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Name of Entity	Grant? Personal Fees? S	n-Financial upport? Comments
Daiichi Sankyo		Daiichi Sankyo employee
Section 4. Intellectual Proper	rty Patents & Copyri	ghts
Do you have any patents, whether plan	ned, pending or issued, bi	oadly relevant to the work? Yes V No

Shi 2



Section 5. Polationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Shi reports personal fees from Daiichi Sankyo outside the submitted work.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Shi 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

van Es 1



Section 1. Identifying Inform	nation				
Given Name (First Name) Nick	2. Surname (Last Name) van Es	3. Date 25-October-2017			
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Gary Raskob			
5. Manuscript Title Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism					
6. Manuscript Identifying Number (if you k 17-11948	now it)				
Section 2. The Work Under C	onsideration for Publi	cation			
any aspect of the submitted work (includin statistical analysis, etc.)? Are there any relevant conflicts of inter	g but not limited to grants, doesn't grants, doesn't grants. Wo commation below. If you have	n a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation, we more than one entity press the "ADD" button to add a row.			
Name of Institution/Company	Grant'	n-Financial Other? Comments			
Daiichi Sankyo		Honorarium			
Section 3. Relevant financial	activities outside the	submitted work.			
of compensation) with entities as descri	ribed in the instructions. Uport relationships that we est? ves No	nether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication .			
Name of Entity	Grant•	n-Financial Other? Comments			
Pfizer		Honorarium			

van Es 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. van Es reports personal fees from Daiichi Sankyo during the conduct of the study; personal fees from Pfizer outside the submitted work.

Evaluation and Feedback

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$

van Es 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Infor	mation		
1. Given Name (First Name) Peter	2. Surname (Last Name Verhamme	e)	3. Date 25-October-2017
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Gary Raskob	g Author's Name
5. Manuscript Title Edoxaban for the Treatment of Cance	r-Associated Venous Th	romboembolism	
6. Manuscript Identifying Number (if you late) 17-11948	know it)		
Section 2. The Work Under (Consideration for Pu	blication	
any aspect of the submitted work (includir statistical analysis, etc.)? Are there any relevant conflicts of inte	ng but not limited to grant: rest? Yes N formation below. If you	s, data monitoring bo	vernment, commercial, private foundation, etc.) for oard, study design, manuscript preparation, ne entity press the "ADD" button to add a row.
Name of Institution/Company	Grant? Personal Fees?	Non-Financial Ot	ther? Comments
Daiichi Sankyo	V		Consultant fees, per-patient fee for clinical study, research grant to institution
Section 3. Relevant financia	l activities outside th	ne submitted wo	rk.
of compensation) with entities as desc	ribed in the instructions eport relationships that	s. Use one line for ea were present duri	financial relationships (regardless of amount ach entity; add as many lines as you need by ng the 36 months prior to publication.
If yes, please fill out the appropriate in			
Name of Entity	Grant? Personal Fees?	Non-Financial Ot	ther? Comments
Bayer Healthcare	V		Consultant, honoraria, research grant to institution
BMS			Consultant, honoraria for lectures



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Boehringer-Ingelheim	✓	✓			Consultant, research grant to institution	
Portola		✓			Constultant	
Medscape		✓			Honoraria	
LeoPharma	✓	✓			Institutional research grant, honoraria for lectures	
Sanofi	✓				Institutional research grant	
Medtronic		✓			Advisory board	
Pfizer		\checkmark			Honoraria for advisory board	
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo						
Section 5. Relationships not c	overed	above				
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? Yes, the following relationships/conditions/circumstances are present (explain below):						
No other relationships/conditions/circumstances that present a potential conflict of interest At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.						

Section 6. Disc

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Verhamme reports grants and personal fees from Daiichi Sankyo, during the conduct of the study; grants and personal fees from Bayer Healthcare, personal fees from BMS, grants and personal fees from Boehringer-Ingelheim, personal fees from Portola, personal fees from Medscape, grants and personal fees from LeoPharma, grants from Sanofi, personal fees from Medtronic, personal fees from Pfizer, outside the submitted work;

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Wang 1



Section 1.	Identifying Inform	nation						
1. Given Name (Fii Tzu-Fei	rst Name)	2. Surname (Last Na Wang	me)		3. Date 24-October-2017			
4. Are you the cor	responding author?	Yes ✓ No	•	Corresponding Author's Name Gary Raskob				
5. Manuscript Title Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism								
6. Manuscript Ider 17-11948	ntifying Number (if you kr	now it)						
Section 2.	The Work Under Co	onsideration for I	Publication					
any aspect of the s statistical analysis, Are there any rela If yes, please fill c	etitution at any time recei ubmitted work (including etc.)? evant conflicts of intere out the appropriate info be removed by pressing	s but not limited to gradest? Yes commation below. If you	nts, data monitorin	g board, study de	esign, manuscript prepa	ration,		
Name of Institut		Grant? Persona	Non-Financial	Other? Cor	nments			
Daiichi Sankyo			✓		l cost for manuscript aration			
Section 3.	Relevant financial	activities outside	the submitted	work.				
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes Vo								
Section 4.	Intellectual Proper	rty Patents & Co	pyrights					
Do you have any	patents, whether plan	ned, pending or issu	ed, broadly releva	ant to the work?	? ☐ Yes ✓ No			

Wang 2



Section 5. Relationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Wang reports non-financial support from Daiichi Sankyo during the conduct of the study.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Wang 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Infor	mation		
1. Given Name (First Name) Jeffrey	2. Surname (Last Name) Weitz		3. Date 25-October-2017
4. Are you the corresponding author?	Yes ✓ No	Corresponding Autho	or's Name
5. Manuscript Title Edoxaban for the Treatment of Cance	er-Associated Venous Thron	mboembolism	
6. Manuscript Identifying Number (if you l 17-11948	know it)		
Section 2. The Work Under (Consideration for Publi	cation	
Did you or your institution at any time recany aspect of the submitted work (includir statistical analysis, etc.)?		. , ,	ent, commercial, private foundation, etc.) for udy design, manuscript preparation,
Are there any relevant conflicts of inte			
If yes, please fill out the appropriate in Excess rows can be removed by pressi	•	ve more than one enti	ty press the "ADD" button to add a row.
Name of Institution/Company	Grant'	on-Financial Support? Other?	Comments
Daiichi-Sankyo			Consultant fees, honoraria
Section 3. Relevant financia	l activities outside the	submitted work.	
of compensation) with entities as desc clicking the "Add +" box. You should re	ribed in the instructions. U eport relationships that we	lse one line for each er	rial relationships (regardless of amount ntity; add as many lines as you need by 26 months prior to publication.
Are there any relevant conflicts of inte If yes, please fill out the appropriate in			
ii yes, picase iiii out tile appropriate iii	normation below.		
Name of Entity	Grant'	on-Financial Support?	Comments
Bayer Healthcare			Consultant, honoraria
BMS			Consultant, honoraria
Boehringer-Ingelheim			Consultant, honoraria



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Ionis Pharmaceuticals		✓			Consultant, honoraria	
Janssen		\checkmark			Consultant, honoraria	
Johnson and Johnson		✓			Consultant, honoraria	
Pfizer		✓			Consultant, honoraria	
Portola		\checkmark			Consultant, honoraria	
Medscape		\checkmark			Consultant, honoraria	
Novartis		✓			Consultant, honoraria	
Section 5. Relationships not	covered	above _				
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work? Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. Section 6. Disclosure Statement						
Disclosure Statement						
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.						
Dr. Weitz reports personal fees from Daiichi-Sankyo, during the conduct of the study; personal fees from Bayer Healthcare, personal fees from BMS, personal fees from Boehringer-Ingelheim, personal fees from Ionis Pharmaceuticals, personal fees from Janssen, personal fees from Johnson and Johnson, personal fees from Pfizer, personal fees from Portola, personal fees from Medscape, personal fees from Novartis outside the submitted work.						



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Information	ation		
1. Given Name (First Name) Erik	2. Surname (La Yeo	st Name)	3. Date 24-October-2017
4. Are you the corresponding author?	☐ Yes ✓	No Correspond Gary Rasko	ding Author's Name ob
5. Manuscript Title Edoxaban for the Treatment of Cancer-A	Associated Ven	ous Thromboembolisn	n
6. Manuscript Identifying Number (if you kno 17-11948	ow it)		
Section 2. The Work Under Co	nsideration	for Publication	
• •			(government, commercial, private foundation, etc.) for g board, study design, manuscript preparation,
Are there any relevant conflicts of interes	st? ✓ Yes	No	
		-	one entity press the "ADD" button to add a row.
Excess rows can be removed by pressing			
Name of Institution/Company	Grant? Pers	onal Non-Financial Support?	Other? Comments
Daiichi Sankyo	V		Clinical trial fees paid to institution for patient enrolled, consultant fees, honoraria
Section 3. Relevant financial a	ctivities out	side the submitted	work.
of compensation) with entities as describ	oed in the instr	uctions. Use one line fo	ave financial relationships (regardless of amount or each entity; add as many lines as you need by uring the 36 months prior to publication.
Are there any relevant conflicts of interes	st? ✓ Yes	No	
If yes, please fill out the appropriate info	rmation below		
N 65 ()	. Pers	onal Non-Financial	
Name of Entity	Grant Fee	2	Other Comments
Bayer Healthcare			Consultant, honoraria
Pfizer			Consultant, honoraria



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Boerhringer Ingelheim		✓			Consultant, honoraria
Sanofi		\checkmark			Consultant, honoraria
.eo Pharma		\checkmark			Consultant, honoraria
Section 4. Intellectual Propert	y Pate	ents & Cop	oyrights		
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo					
Section 5. Relationships not covered above					
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?					
Yes, the following relationships/conditions/circumstances are present (explain below):					
✓ No other relationships/conditions/circumstances that present a potential conflict of interest					finterest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.					
Section 6. Disclosure Statemen	nt				
Based on the above disclosures, this form below.	n will auto	omatically (generate a disclos	sure state	ment, which will appear in the box
Dr. Yeo reports grants and personal fees Healthcare, personal fees from Pfizer, pe fees from Leo Pharma outside the submi	rsonal fe	es from Boo			



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Zhang 1



Section 1.	Identifying Inform	nation			
1. Given Name (Fi George	rst Name)	2. Surname (Last Name) Zhang		3. Date 25-October-2017	
4. Are you the cor	responding author?	Yes 🗸 No	Corresponding Author's Name Gary Raskob		
5. Manuscript Title Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism					
6. Manuscript Ider 17-11948	ntifying Number (if you kr	now it)			
	l				
Section 2.	The Work Under Co	onsideration for Publi	cation		
any aspect of the s statistical analysis, Are there any rel	ubmitted work (including	but not limited to grants, d		commercial, private foundation, etc.) for design, manuscript preparation,	
Section 3.	Relevant financial	activities outside the	submitted work.		
of compensation clicking the "Add Are there any rel) with entities as descri	ibed in the instructions. Uport relationships that weest? Yes No	se one line for each entity	relationships (regardless of amount y; add as many lines as you need by 5 months prior to publication .	
Name of Entity		Granic	n-Financial Other? C	Comments	
Daiichi Sankyo			Dai	iichi Sankyo employee	
Section 4.	Intellectual Proper	rty Patents & Copyri	ghts		
Do you have any	patents, whether plan	ned, pending or issued, b	roadly relevant to the wo	rk? ☐ Yes ✓ No	

Zhang 2



Section 5. Polationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Zhang reports personal fees from Daiichi Sankyo outside the submitted work.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Zhang 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Zwicker 1



Identifying Information

Section 1.

ICMJE Form for Disclosure of Potential Conflicts of Interest

Given Name (First Name) Jeffrey	2. Surname (Last Name) Zwicker		3. Date 24-October-2017
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's N Gary Raskob	ame
5. Manuscript Title Edoxaban for the Treatment of Cancer-	Associated Venous Thron	nboembolism	
6. Manuscript Identifying Number (if you kn	now it)	_	
Section 2. The Work Under Co			
The work onder Co	onsideration for Public		
Did you or your institution at any time recei any aspect of the submitted work (including statistical analysis, etc.)?	but not limited to grants, da		
Are there any relevant conflicts of intere		.1	
If yes, please fill out the appropriate info Excess rows can be removed by pressing		e more than one entity pr	ress the "ADD" button to add a row.
Name of Institution/Company	Grant	n-Financial other? Co	omments
Daiichi Sankyo			orarium for manuscript paration
Section 3. Belovent financial			
Relevant financial	activities outside the s	submitted work.	
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep	bed in the instructions. Us	se one line for each entity;	add as many lines as you need by
Are there any relevant conflicts of intere			
If yes, please fill out the appropriate info	ormation below.		
Name of Entity	Grant	n-Financial Other? Co	omments
Quercegen Pharma	✓		
Parexel		Con	sulting

Zwicker 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume No
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Zwicker reports personal fees from Daiichi Sankyo during the conduct of the study; grants from Quercegen Pharma and personal fees from Parexel outside the submitted work.

Evaluation and Feedback

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$

Zwicker 3